Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: A randomized, double-blind trial

Journal of Dermatological Treatment

Volumn 21, Issue 3, 2010, Pages 157-166

  Meurer, Michael ^a   Eichenfield, Lawrence F ^b   Ho, Vincent ^c   Potter, Paul C ^d   Werfel, Thomas ^e   Hultsch, Thomas ^f  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fluticasone; Paediatric; Pimecrolimus; Severe atopic dermatitis; Topical corticosteroids

Indexed keywords

FLUTICASONE PROPIONATE; PIMECROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ERYTHEMA; FEMALE; FOLLICULITIS; HERPES SIMPLEX; HUMAN; INFESTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; SKIN BURNING SENSATION; SKIN PRURITUS; TELANGIECTASIA; URINARY TRACT INFECTION; URTICARIA; VOMITING;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANDROSTADIENES; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 77951126005     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903410158     Document Type: Article

References (21)

1. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120:150-155.
2. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121: 1337-1343.
3. Elias PM, Steinhoff M. Outside-to-inside (and now back to outside) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128:1067-1070.
4. Wollenberg A, Klein E. Current aspects of innate and adaptive immunity in atopic dermatitis. Clin Rev Allergy Immunol. 2007;33:35-44.
5. Leung DYM. Atopic dermatitis: Immunology and treatment with immune modulators. Clin Exp Immunol. 1997;107 (suppl 1):25-30.
6. Paller AS, McAllister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41: 323-332.
7. Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz- Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1): 226-232.
8. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene- environment interactions. J Allergy Clin Immunol. 2006;118(1):3-21.
9. Darsow U, Lübbe J, Taïeb A, Seidenari S, Wollenberg A, Calza AM et al., for the European Task Force on Atopic Dermatitis. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2005;19 (3):286-295.
10. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Treatment of atopic dermatitis and impact on quality of life: A review with emphasis on topical non-corticosteroids. Pharmacoeconomics. 2003;21(3):159-179.
11. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic- pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Paediatrics. 2000;105:794-799.
12. Charman CR, Morris AD, Williams HC. Topical corticosteroids phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-936.
13. Magiakou MA, Chrousos GP. Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Curr Ther Endocrinol Metab. 1997;6:138-142.
14. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
15. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al., for the Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110:e2.
16. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, et al., for the CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004;208:365-372. (Pubitemid 38736667)
17. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol. 2001;144(3):507-513.
18. Sigurgeirsson B, Ho V, Ferrándiz C, Andriano K, Grinienko A, Jimenez P. Effectiveness and safety of a prevention- of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290-1301.
19. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987;139(12): 4129-4134.
20. Barnes PJ, Karin M. Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066-1071.
21. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol. 2003;17(5):493-503.